lenvatinib Mesylate
- Product Name
- lenvatinib Mesylate
- CAS No.
- 857890-39-2
- Chemical Name
- lenvatinib Mesylate
- Synonyms
- Lenvatinib mesilate;4-[3-Chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-6-quinolinecarboxamide monomethanesulfonate;CAT#A863437;E7080 Mesylate;envatinib MesyL;Lenvatinib Meylate;Levatinib mesylate;Lenvatinib Mesylat;levitinib mesylate;E7080;E-7080;E 7080
- CBNumber
- CB42651170
- Molecular Formula
- C22H23ClN4O7S
- Formula Weight
- 522.95862
- MOL File
- 857890-39-2.mol
lenvatinib Mesylate Property
- Melting point:
- >220°C (dec.)
- storage temp.
- -20°C Freezer
- solubility
- DMSO (Slightly), Methanol (Slightly)
- form
- Solid
- color
- White to Off-White
- InChIKey
- HWLFIUUAYLEFCT-UHFFFAOYSA-N
- SMILES
- O=C(N)C1C=C2C(N=CC=C2OC2C=C(Cl)C(NC(=O)NC3CC3)=CC=2)=CC=1OC.CS(=O)(O)=O
Hazard and Precautionary Statements (GHS)
- Symbol(GHS)
-
- Signal word
- Warning
- Hazard statements
-
H302Harmful if swallowed
H315Causes skin irritation
H319Causes serious eye irritation
H335May cause respiratory irritation
- Precautionary statements
-
P261Avoid breathing dust/fume/gas/mist/vapours/spray.
P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.
N-Bromosuccinimide Price
- Product number
- SML3017
- Product name
- Lenvatinib mesylate
- Purity
- ≥98% (HPLC)
- Packaging
- 10MG
- Price
- $94.2
- Updated
- 2024/03/01
- Product number
- SML3017
- Product name
- Lenvatinib mesylate
- Purity
- ≥98% (HPLC)
- Packaging
- 50MG
- Price
- $381
- Updated
- 2024/03/01
- Product number
- 29832
- Product name
- Lenvatinib (mesylate)
- Packaging
- 500mg
- Price
- $86
- Updated
- 2024/03/01
- Product number
- 29832
- Product name
- Lenvatinib (mesylate)
- Packaging
- 5g
- Price
- $421
- Updated
- 2024/03/01
- Product number
- 29832
- Product name
- Lenvatinib (mesylate)
- Packaging
- 1g
- Price
- $135
- Updated
- 2024/03/01
lenvatinib Mesylate Chemical Properties,Usage,Production
Description
Lenvatinib mesylate (lenvatinib) is an oral targeted therapy medicine known as a receptor‐type tyrosine kinase inhibitor. It is a small-molecule drug (a drug that can enter cells easily), which was developed at Eisai in 2015. It was approved by the FDA in 2015 for the treatment of differentiated thyroid cancer that is either locally recurrent, metastatic, or progressive and did not respond to radioactive iodine treatment. In May 2016, the FDA approved the drug as a combination therapy with everolimus for the treatment of advanced renal cell carcinoma. Because VEGF (and fibroblast growth factor receptors, known as FGFRs) are thought to play a role in cardiovascular signaling pathways, VEGF2R and FGFR inhibition are thought to be the mechanisms behind the primary side effect of lenvatinib mesylate, which is hypertension.
Uses
Lenvatinib mesylate is used in cancer:(1) Endometrial carcinoma that is advanced and got worse after other systemic therapies. It is used with pembrolizumab in patients whose cancer is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) and cannot be treated with surgery or radiation therapy.(2) Hepatocellular carcinoma (a type of liver cancer). It is used as the first treatment in patients whose cancer cannot be removed by surgery.(3) Renal cell carcinoma (a type of kidney cancer) that is advanced(4)Thyroid cancer in certain patients whose cancer got worse, came back, or has spread to other parts of the body and did not respond to treatment with radioactive iodine.(5) Lenvatinib Mesylate is used in preparation of anti-human CTLA4xPD-1 bispecific antibodies for diagnosis, prevention and treatment of tumor or anemia.
Lenvatinib mesylate is also being studied in the treatment of other types of cancer.
Uses
E7080 (Lenvatinib) is a multi-target inhibitor of VEGFR2 and VEGFR3 with IC50 of 4 nM and 5.2 nM, respectively.
Definition
ChEBI: Lenvatinib mesylate is a methanesulfonate salt obtained by reaction of lenvatinib with one molar equivalent of methanesulfonic acid. A multi-kinase inhibitor and orphan drug used (as its mesylate salt) for the treatment of various types of thyroid cancer that do not respond to radioiodine. It has a role as an EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor, a fibroblast growth factor receptor antagonist, an orphan drug, a vascular endothelial growth factor receptor antagonist and an antineoplastic agent. It contains a lenvatinib(1+).
Mechanism of action
Lenvatinib mesylate works by blocking proteins that signal cancer cells to multiply. It also blocks proteins that signal the formation of new blood vessels that are needed to support tumor growth. Blocking these signals keeps cancer cells from growing.
Pharmacokinetics
Lenvatinib is rapidly absorbed after oral administration, with tmax typically observed at 1 to 4 hours postdose. Food does not affect the extent of absorption but slows the rate of absorption. When administered with food to healthy subjects, peak plasma concentrations are delayed by 2 hours.
In vitro binding of lenvatinib to human plasma proteins was high and ranged from 98% to 99% (0.3 – 30 μg/mL, lenvatinib Mesylate). This binding was mainly to albumin with minor binding to α1-acid glycoprotein and γ-globulin. In vitro, the lenvatinib blood-to-plasma concentration ratio ranged from 0.589 to 0.608 (0.1 - 10 μg/mL, lenvatinib Mesylate). Lenvatinib is a substrate for P-gp and BCRP. Lenvatinib is not a substrate for OAT1, OAT3, OATP1B1, OATP1B3, OCT1, OCT2, or the BSEP.
Side effects
The most prevalent AEs were hypertension (77.8%), fatigue (55.6%), weight loss (51.9%).In addition, there may be fatigue or tiredness, rashes, redness, itching or peeling of the palms and soles of the feet, diarrhoea, nausea, constipation and heartburn.
Synthesis
Starting from commercial aniline
193, a substitution reaction under neutral conditions in warm
isopropyl alcohol with a commercial vinyl methoxy derivative of
Meldrum?ˉs acid (194) produced enamine 195 in good yield.
Next, subjection of 195 to DOWTHERM A at 190 ??C affected
an intramolecular cyclizative substitution reaction, followed by
loss of acetone, and a decarboxylation reaction to furnish
quinolone 196. This cyclization reaction, which is a variant of
the Conrad-Limpach reaction, is particularly noteworthy
given the temperature and pH at which it takes place. Conrad-
Limpach cyclizations typically proceed under basic conditions
at temperatures well above 240 ??C. However, a process was
developed by Zeneca in 2004 which involved subjecting 195 to
the DOWTHERM heat transfer fluid (commercially available
from Dow and Sigma-Aldrich, consisting of a eutectic mixture
of biphenyl and diphenyl oxide) allowed the team to lower
the temperature required for the reaction, clearly observe
bubbling of gas indicating the progress of the reaction, and
simple cooling and treatment with ether to facilitated
precipitate formation. The resulting solid could be collected
by filtration and required no additional purification on scale in
80% yield. Quinoline 196 was then converted to the
corresponding chloride using thionyl chloride in refluxing
DMF, and the resulting ester 197 was converted to the
corresponding amide through the use of 28% aqueous
ammonia in warm ethanol, which ultimately produced the
key chloroquinoline lenvatinib subunit 198 in 80% yield from
197.
Commercial aminophenol 199 was
converted to the corresponding carbamate through the use of
phenyl chloroformate in essentially quantitative yield prior to
subjection to cyclopropylamine in chilled DMF, which
ultimately furnished urea 201 in 77% overall yield from 200.
Next, exposure of phenol 201 to chloroquinoline 198 in the presence of potassium t-butoxide followed by
treatment with methanesulfonic acid and acetic acid resulted in
clean formation of lenvatinib mesylate (XXV) in 96% yield
across the two-step sequence.
Solubility in water
lenvatinib Mesylate is a white powder sparingly soluble in acetic acid and slightly soluble in water. It is very slightly soluble in 1,3-dimethyl-2-imidazolidinone and practically insoluble in acetonitrile, dehydrated ethanol, 1-propanol, 2-propanol, 1-octanol, and isopropyl acetate. In aqueous solutions, lenvatinib mesylate is slightly soluble in 0.1 mol/L HCl and practically insoluble in Britton-Robinson buffer, pH 3-11.
lenvatinib Mesylate Preparation Products And Raw materials
Raw materials
Preparation Products
lenvatinib Mesylate Suppliers
- Tel
- --
- Fax
- --
- @pharmaffiliates.com
- Country
- India
- ProdList
- 6754
- Advantage
- 58
- Tel
- --
- Fax
- --
- standards@synzeal.com
- Country
- India
- ProdList
- 6514
- Advantage
- 58
- Tel
- --
- Fax
- --
- mktg@pharmaffiliates.com
- Country
- India
- ProdList
- 6739
- Advantage
- 58
- Tel
- --
- Fax
- --
- sales@ajchem.in
- Country
- India
- ProdList
- 6100
- Advantage
- 58
- Tel
- --
- Fax
- --
- info@msnlabs.com
- Country
- India
- ProdList
- 230
- Advantage
- 58
- Tel
- --
- Fax
- --
- info@vbshilpa.com
- Country
- India
- ProdList
- 52
- Advantage
- 58
- Tel
- --
- Fax
- --
- secretarial@sunpharma.com
- Country
- India
- ProdList
- 175
- Advantage
- 58
- Tel
- --
- Fax
- --
- krishnaraoy@drreddys.com
- Country
- India
- ProdList
- 201
- Advantage
- 58
View Lastest Price from lenvatinib Mesylate manufacturers
- Product
- Lenvatinib Mesylate 857890-39-2
- Price
- US $0.00-0.00/kg
- Min. Order
- 1kg
- Purity
- ＞99% by HPLC
- Supply Ability
- 10kg/month
- Release date
- 2023-01-06
- Product
- Lenvatinib mesylate 857890-39-2
- Price
- US $0.00-0.00/Kg/Bag
- Min. Order
- 2Kg/Bag
- Purity
- 99% up /EP
- Supply Ability
- 20 tons
- Release date
- 2023-11-14
- Product
- lenvatinib Mesylate 857890-39-2
- Price
- US $1.00-0.50/kg
- Min. Order
- 1kg
- Purity
- 99%
- Supply Ability
- 200kg
- Release date
- 2023-12-11